Evaluation about clinical curative effect of treatment of non-small cell lung cancer with autologous and half consistency allograft cytokines induced killer cells combined with chemotherapy / 肿瘤研究与临床

ABSTRACT

Objective To evaluate the clinical efficacy and safety of treatment of non-small cell lung cancer (NSCLC) with autologous and half consistency allograft cytokines induced killer cells combined with chemotherapy. Methods We selected 42 patients with NSCLC patients as the research object. According to the group matching principle, the cases were divided into three groups autologous CIK cells combination chemotherapy group, half consistency allograft CIK cells combination chemotherapy group, pure chemotherapy group. The autologous and allograft CIK cellular immune therapy of security, flow cytometric analysis technique (FCM) comparisons between before and after the treatment group infusion in vivo T lymphocyte subsets changes, and three treatment group clinical short-term curative effect were used in the comparison.Results FCM detection results show that CIK cell infusion after, CD+3, CD+4 / CD+8 ratio, NK cells (CD+3 CD+56)and CIK cells (CD+3 CD+56) ratio obviously higher than before treatment, autologous infusion before treatment,respectively (47.2±10.1) %, 1.0±0.1, (15.1±2.7) %, (0.7±0.2) %. After treatment respectively (58.8±12.3) %,1.3±0.2, (24.6±7.1) %, (3.8±2.2) %; Allograft infusion before treatment for (49.4±11.4) %, 0.9±0.2, (14.8±3.2) %, (0.9±0.3) % for after treatment (57.3±9.2) %, 1.4±0.3, (25.4±6.7) %, (4.3 ± 2.6) % (t = 22, 20, 19,P ＜ 0.05), and the pure chemotherapy group before and after the treatment T lymphocyte subsets level has not seen the obvious change. Clinical short-term curative effect comparison, autologous and allograft CIK cell therapy group objective efficient and disease control rates are slightly higher than the pure chemotherapy group, but the difference was not statistically significant. Respectively 21.4 %, 57.1%, and 35.7 %, 28.6 %,64.3 %, 71.4 % (x2=38.85, x2=41.24, P ＞ 0.05). Conclusion Autologous or half consistency allograft CIK cellular immune therapy is good safety and low toxicity, have certain short-term curative effect, which can effectively slowed tumor recurrence, is a worthy of popularizing clinically tumor adjuvant treatment mode.